• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Benzinga's Top Ratings Upgrades, Downgrades For August 28, 2023

    8/28/23 11:00:48 AM ET
    $AENT
    $AGIL
    $AIRC
    $AKBA
    Durable Goods
    Consumer Discretionary
    Professional Services
    Consumer Discretionary
    Get the next $AENT alert in real time by email

    Upgrades

    According to B of A Securities, the prior rating for Futu Holdings Ltd (NASDAQ:FUTU) was changed from Underperform to Buy. In the second quarter, Futu Hldgs showed an EPS of $1.09, compared to $0.61 from the year-ago quarter. The stock has a 52-week-high of $72.20 and a 52-week-low of $28.01. At the end of the last trading period, Futu Hldgs closed at $51.06.

    According to Truist Securities, the prior rating for Apartment Income REIT Corp (NYSE:AIRC) was changed from Hold to Buy. In the second quarter, Apartment Income REIT showed an EPS of $0.58, compared to $0.66 from the year-ago quarter. At the moment, the stock has a 52-week-high of $43.70 and a 52-week-low of $32.51. Apartment Income REIT closed at $33.49 at the end of the last trading period.

    According to Truist Securities, the prior rating for UDR Inc (NYSE:UDR) was changed from Hold to Buy. UDR earned $0.61 in the second quarter, compared to $0.57 in the year-ago quarter. The current stock performance of UDR shows a 52-week-high of $48.31 and a 52-week-low of $37.18. Moreover, at the end of the last trading period, the closing price was at $39.17.

    For MACOM Technology Solutions Holdings Inc (NASDAQ:MTSI), Benchmark upgraded the previous rating of Hold to Buy. For the third quarter, MACOM Technology Solns had an EPS of $0.54, compared to year-ago quarter EPS of $0.73. The current stock performance of MACOM Technology Solns shows a 52-week-high of $81.54 and a 52-week-low of $48.53. Moreover, at the end of the last trading period, the closing price was at $80.04.

    For Emerson Electric Co (NYSE:EMR), Argus Research upgraded the previous rating of Hold to Buy. Emerson Electric earned $1.29 in the third quarter, compared to $1.38 in the year-ago quarter. At the moment, the stock has a 52-week-high of $99.65 and a 52-week-low of $72.42. Emerson Electric closed at $97.64 at the end of the last trading period.

    For Church & Dwight Co Inc (NYSE:CHD), Truist Securities upgraded the previous rating of Hold to Buy. For the second quarter, Church & Dwight Co had an EPS of $0.92, compared to year-ago quarter EPS of $0.76. At the moment, the stock has a 52-week-high of $100.52 and a 52-week-low of $70.16. Church & Dwight Co closed at $93.30 at the end of the last trading period.

    For AppFolio Inc (NASDAQ:APPF), William Blair upgraded the previous rating of Market Perform to Outperform. For the second quarter, AppFolio had an EPS of $0.23, compared to year-ago quarter EPS of $0.03. The stock has a 52-week-high of $195.90 and a 52-week-low of $93.04. At the end of the last trading period, AppFolio closed at $183.82.

    According to HC Wainwright & Co., the prior rating for Akebia Therapeutics Inc (NASDAQ:AKBA) was changed from Neutral to Buy. In the second quarter, Akebia Therapeutics showed an EPS of $0.06, compared to $0.15 from the year-ago quarter. The stock has a 52-week-high of $1.84 and a 52-week-low of $0.24. At the end of the last trading period, Akebia Therapeutics closed at $1.15.

    Wells Fargo upgraded the previous rating for UGI Corp (NYSE:UGI) from Equal-Weight to Overweight. In the third quarter, UGI showed an EPS of $0.00, compared to $0.06 from the year-ago quarter. At the moment, the stock has a 52-week-high of $43.19 and a 52-week-low of $22.45. UGI closed at $22.71 at the end of the last trading period.

    BTIG upgraded the previous rating for Zimmer Biomet Holdings Inc (NYSE:ZBH) from Neutral to Buy. In the second quarter, Zimmer Biomet Holdings showed an EPS of $1.82, compared to $1.82 from the year-ago quarter. The current stock performance of Zimmer Biomet Holdings shows a 52-week-high of $149.25 and a 52-week-low of $102.60. Moreover, at the end of the last trading period, the closing price was at $115.24.

    According to Piper Sandler, the prior rating for Mister Car Wash Inc (NYSE:MCW) was changed from Neutral to Overweight. In the second quarter, Mister Car Wash showed an EPS of $0.08, compared to $0.11 from the year-ago quarter. At the moment, the stock has a 52-week-high of $11.14 and a 52-week-low of $6.43. Mister Car Wash closed at $6.89 at the end of the last trading period.

    See all analyst ratings upgrades.

    Downgrades

    HC Wainwright & Co. downgraded the previous rating for NovoCure Ltd (NASDAQ:NVCR) from Buy to Neutral. For the second quarter, NovoCure had an EPS of $0.54, compared to year-ago quarter EPS of $0.23. At the moment, the stock has a 52-week-high of $120.03 and a 52-week-low of $26.68. NovoCure closed at $29.77 at the end of the last trading period.

    Alliance Global Partners downgraded the previous rating for AgileThought Inc (NASDAQ:AGIL) from Buy to Sell. For the second quarter, AgileThought had an EPS of $0.13, compared to year-ago quarter EPS of $0.04. The current stock performance of AgileThought shows a 52-week-high of $4.80 and a 52-week-low of $0.20. Moreover, at the end of the last trading period, the closing price was at $0.26.

    For VMware Inc (NYSE:VMW), Monness, Crespi, Hardt downgraded the previous rating of Buy to Neutral. For the first quarter, VMware had an EPS of $1.49, compared to year-ago quarter EPS of $1.28. The stock has a 52-week-high of $170.00 and a 52-week-low of $104.03. At the end of the last trading period, VMware closed at $162.55.

    Truist Securities downgraded the previous rating for Essex Property Trust Inc (NYSE:ESS) from Buy to Hold. In the second quarter, Essex Property Trust showed an EPS of $3.77, compared to $3.68 from the year-ago quarter. The current stock performance of Essex Property Trust shows a 52-week-high of $284.02 and a 52-week-low of $195.03. Moreover, at the end of the last trading period, the closing price was at $237.24.

    For Energizer Holdings Inc (NYSE:ENR), Truist Securities downgraded the previous rating of Buy to Hold. For the third quarter, Energizer Hldgs had an EPS of $0.54, compared to year-ago quarter EPS of $0.77. At the moment, the stock has a 52-week-high of $37.89 and a 52-week-low of $24.81. Energizer Hldgs closed at $34.56 at the end of the last trading period.

    Wells Fargo downgraded the previous rating for Atmos Energy Corp (NYSE:ATO) from Overweight to Equal-Weight. In the third quarter, Atmos Energy showed an EPS of $0.94, compared to $0.92 from the year-ago quarter. The current stock performance of Atmos Energy shows a 52-week-high of $125.28 and a 52-week-low of $97.83. Moreover, at the end of the last trading period, the closing price was at $117.70.

    For Upwork Inc (NASDAQ:UPWK), BTIG downgraded the previous rating of Buy to Neutral. Upwork earned $0.10 in the second quarter, compared to $0.04 in the year-ago quarter. At the moment, the stock has a 52-week-high of $18.57 and a 52-week-low of $6.56. Upwork closed at $14.75 at the end of the last trading period.

    HC Wainwright & Co. downgraded the previous rating for Timber Pharmaceuticals Inc (AMEX:TMBR) from Buy to Neutral. Timber Pharmaceuticals earned $1.32 in the second quarter, compared to $7.50 in the year-ago quarter. At the moment, the stock has a 52-week-high of $8.72 and a 52-week-low of $1.21. Timber Pharmaceuticals closed at $3.03 at the end of the last trading period.

    Jefferies downgraded the previous rating for Denbury Inc (NYSE:DEN) from Buy to Hold. For the second quarter, Denbury had an EPS of $1.06, compared to year-ago quarter EPS of $1.69. The stock has a 52-week-high of $104.05 and a 52-week-low of $73.24. At the end of the last trading period, Denbury closed at $89.25.

    JP Morgan downgraded the previous rating for Lyell Immunopharma Inc (NASDAQ:LYEL) from Overweight to Neutral. Lyell Immunopharma earned $0.04 in the second quarter, compared to $0.04 in the year-ago quarter. The current stock performance of Lyell Immunopharma shows a 52-week-high of $8.74 and a 52-week-low of $1.77. Moreover, at the end of the last trading period, the closing price was at $2.29.

    For CrowdStrike Holdings Inc (NASDAQ:CRWD), Morgan Stanley downgraded the previous rating of Overweight to Equal-Weight. CrowdStrike Holdings earned $0.57 in the first quarter, compared to $0.31 in the year-ago quarter. At the moment, the stock has a 52-week-high of $203.59 and a 52-week-low of $92.25. CrowdStrike Holdings closed at $149.58 at the end of the last trading period.

    For Century Therapeutics Inc (NASDAQ:IPSC), JP Morgan downgraded the previous rating of Overweight to Neutral. Century Therapeutics earned $0.56 in the second quarter, compared to $0.54 in the year-ago quarter. At the moment, the stock has a 52-week-high of $11.95 and a 52-week-low of $2.28. Century Therapeutics closed at $2.39 at the end of the last trading period.

    For L3Harris Technologies Inc (NYSE:LHX), Bernstein downgraded the previous rating of Outperform to Market Perform. For the second quarter, L3Harris Technologies had an EPS of $2.97, compared to year-ago quarter EPS of $6.38. The current stock performance of L3Harris Technologies shows a 52-week-high of $255.02 and a 52-week-low of $174.55. Moreover, at the end of the last trading period, the closing price was at $178.46.

    See all analyst ratings downgrades.

    Initiations

    With a Buy rating, UBS initiated coverage on 89bio Inc (NASDAQ:ETNB). The price target seems to have been set at $36.00 for 89bio. For the second quarter, 89bio had an EPS of $0.52, compared to year-ago quarter EPS of $1.23. At the moment, the stock has a 52-week-high of $22.93 and a 52-week-low of $4.18. 89bio closed at $16.52 at the end of the last trading period.

    UBS initiated coverage on Akero Therapeutics Inc (NASDAQ:AKRO) with a Buy rating. The price target for Akero Therapeutics is set to $83.00. For the second quarter, Akero Therapeutics had an EPS of $0.60, compared to year-ago quarter EPS of $0.77. The stock has a 52-week-high of $58.38 and a 52-week-low of $10.49. At the end of the last trading period, Akero Therapeutics closed at $47.97.

    With a Buy rating, Craig-Hallum initiated coverage on Xeris Biopharma Holdings Inc (NASDAQ:XERS). The price target seems to have been set at $4.50 for Xeris Biopharma Holdings. For the second quarter, Xeris Biopharma Holdings had an EPS of $0.14, compared to year-ago quarter EPS of $0.19. The current stock performance of Xeris Biopharma Holdings shows a 52-week-high of $3.07 and a 52-week-low of $0.97. Moreover, at the end of the last trading period, the closing price was at $2.15.

    For Bio-Techne Corp (NASDAQ:TECH), William Blair initiated coverage, by setting the current rating at Outperform. Bio-Techne earned $0.55 in the fourth quarter, compared to $0.51 in the year-ago quarter. The stock has a 52-week-high of $90.34 and a 52-week-low of $68.30. At the end of the last trading period, Bio-Techne closed at $80.16.

    With a Buy rating, ThinkEquity initiated coverage on Alliance Entertainment Holding Corp (NASDAQ:AENT). The price target seems to have been set at $6.00 for Alliance Entertainment. The stock has a 52-week-high of $4.20 and a 52-week-low of $1.71. At the end of the last trading period, Alliance Entertainment closed at $2.20.

    Cantor Fitzgerald initiated coverage on NextGen Healthcare Inc (NASDAQ:NXGN) with an Overweight rating. The price target for NextGen Healthcare is set to $21.00. In the first quarter, NextGen Healthcare showed an EPS of $0.24, compared to $0.16 from the year-ago quarter. The stock has a 52-week-high of $21.92 and a 52-week-low of $15.23. At the end of the last trading period, NextGen Healthcare closed at $17.95.

    With a Buy rating, Seaport Global initiated coverage on Liberty Live Group (NASDAQ:LLYVA). The price target seems to have been set at $56.00 for Liberty Live. The stock has a 52-week-high of $37.00 and a 52-week-low of $32.07. At the end of the last trading period, Liberty Live closed at $33.16.

    With a Neutral rating, Citigroup initiated coverage on Cricut Inc (NASDAQ:CRCT). The price target seems to have been set at $10.50 for Cricut. Cricut earned $0.07 in the second quarter, compared to $0.06 in the year-ago quarter. At the moment, the stock has a 52-week-high of $17.89 and a 52-week-low of $6.04. Cricut closed at $9.27 at the end of the last trading period.

    HC Wainwright & Co. initiated coverage on Reneo Pharmaceuticals Inc (NASDAQ:RPHM) with a Buy rating. The price target for Reneo Pharmaceuticals is set to $30.00. For the second quarter, Reneo Pharmaceuticals had an EPS of $0.65, compared to year-ago quarter EPS of $0.50. The stock has a 52-week-high of $11.29 and a 52-week-low of $1.79. At the end of the last trading period, Reneo Pharmaceuticals closed at $6.25.

    Canaccord Genuity initiated coverage on Surf Air Mobility Inc (NYSE:SRFM) with a Buy rating. The price target for Surf Air Mobility is set to $3.00. The stock has a 52-week-high of $5.00 and a 52-week-low of $1.10. At the end of the last trading period, Surf Air Mobility closed at $1.34.

    Goldman Sachs initiated coverage on Corporacion Inmobiliaria Vesta SAB de CV (NYSE:VTMX) with a Neutral rating. The price target for Corporacion Inmobiliaria is set to $36.00. For the second quarter, Corporacion Inmobiliaria had an EPS of $0.01, compared to year-ago quarter EPS of $0.02. The current stock performance of Corporacion Inmobiliaria shows a 52-week-high of $38.62 and a 52-week-low of $31.50. Moreover, at the end of the last trading period, the closing price was at $37.79.

    With an Outperform rating, Wolfe Research initiated coverage on Workiva Inc (NYSE:WK). The price target seems to have been set at $120.00 for Workiva. In the second quarter, Workiva showed an EPS of $0.02, compared to $0.17 from the year-ago quarter. At the moment, the stock has a 52-week-high of $112.21 and a 52-week-low of $60.33. Workiva closed at $100.06 at the end of the last trading period.

    RBC Capital initiated coverage on Tetra Tech Inc (NASDAQ:TTEK) with an Outperform rating. The price target for Tetra Tech is set to $181.00. Tetra Tech earned $1.29 in the third quarter, compared to $1.08 in the year-ago quarter. The current stock performance of Tetra Tech shows a 52-week-high of $173.27 and a 52-week-low of $122.86. Moreover, at the end of the last trading period, the closing price was at $157.24.

    With a Buy rating, Laidlaw & Co. initiated coverage on SILO Pharma Inc (NASDAQ:SILO). The price target seems to have been set at $10.00 for SILO Pharma. The current stock performance of SILO Pharma shows a 52-week-high of $12.22 and a 52-week-low of $1.71. Moreover, at the end of the last trading period, the closing price was at $1.94.

    With a Market Outperform rating, JMP Securities initiated coverage on Pagaya Technologies Ltd (NASDAQ:PGY). The price target seems to have been set at $2.75 for Pagaya Techs. Pagaya Techs earned $0.00 in the second quarter, compared to $0.00 in the year-ago quarter. The current stock performance of Pagaya Techs shows a 52-week-high of $14.82 and a 52-week-low of $0.57. Moreover, at the end of the last trading period, the closing price was at $1.95.

    See all analyst ratings initiations.

    Get the next $AENT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AENT
    $AGIL
    $AIRC
    $AKBA

    CompanyDatePrice TargetRatingAnalyst
    Emerson Electric Company
    $EMR
    2/5/2026$170.00Buy → Hold
    Deutsche Bank
    Futu Holdings Limited
    $FUTU
    2/2/2026$213.39Neutral → Buy
    Goldman
    Church & Dwight Company Inc.
    $CHD
    2/2/2026$100.00Underweight → Neutral
    Analyst
    Emerson Electric Company
    $EMR
    1/27/2026Outperform → Perform
    Oppenheimer
    UDR Inc.
    $UDR
    1/20/2026Hold → Buy
    Truist
    CrowdStrike Holdings Inc.
    $CRWD
    1/12/2026Overweight → Sector Weight
    KeyBanc Capital Markets
    Zimmer Biomet Holdings Inc.
    $ZBH
    1/9/2026$93.00Neutral → Sell
    Goldman
    Essex Property Trust Inc.
    $ESS
    1/9/2026$280.00Outperform → Market Perform
    BMO Capital Markets
    More analyst ratings

    $AENT
    $AGIL
    $AIRC
    $AKBA
    SEC Filings

    View All

    NovoCure Limited filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - NovoCure Ltd (0001645113) (Filer)

    2/11/26 5:24:45 PM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    Bio-Techne Corp filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - BIO-TECHNE Corp (0000842023) (Filer)

    2/11/26 4:30:18 PM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 8-K filed by Atmos Energy Corporation

    8-K - ATMOS ENERGY CORP (0000731802) (Filer)

    2/10/26 5:12:33 PM ET
    $ATO
    Oil/Gas Transmission
    Utilities

    $AENT
    $AGIL
    $AIRC
    $AKBA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Hill Stephen J. was granted 4,000 shares and sold $2,520 worth of shares (109 units at $23.12), increasing direct ownership by 26% to 19,031 units (SEC Form 4)

    4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)

    2/11/26 9:05:21 PM ET
    $LYEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Scientific Officer Lee Gary K. was granted 4,000 shares and sold $3,399 worth of shares (147 units at $23.12), increasing direct ownership by 26% to 18,609 units (SEC Form 4)

    4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)

    2/11/26 9:04:20 PM ET
    $LYEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Seely Lynn was granted 20,000 shares and sold $10,127 worth of shares (438 units at $23.12), increasing direct ownership by 31% to 81,721 units (SEC Form 4)

    4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)

    2/11/26 9:03:03 PM ET
    $LYEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AENT
    $AGIL
    $AIRC
    $AKBA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    U.S. FDA Approves Novocure's Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer

    Optune Pax concomitant with gemcitabine and nab-paclitaxel is the first treatment to be FDA approved in nearly 30 years for locally advanced pancreatic cancer Phase 3 PANOVA-3 trial showed a statistically significant improvement in overall survival (OS) and significantly extended time to pain progression in patients treated with Optune Pax Optune Pax is a wearable medical device that delivers Tumor Treating Fields (TTFields), alternating electric fields that disrupt cancer cell replication to cause cell death, providing a new treatment approach for pancreatic tumors Novocure (NASDAQ:NVCR) announced today that the U.S. Food and Drug Administration (FDA) approved Optune Pax® for the tre

    2/11/26 5:54:00 PM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    Bio-Techne Announces Changes to its Leadership Team

    Dr. Matt McManus to transition from his role as President, Diagnostics and Spatial Biology Segment, effective March 1, 2026Steve Crouse, Senior Vice President of Bio-Techne's Analytical Solutions Division, has been appointed President, Diagnostics and Spatial Biology Segment, effective March 1, 2026MINNEAPOLIS, Feb. 11, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Dr. Matt McManus, President of Bio-Techne's Diagnostics and Spatial Biology Segment, will be transitioning from his role, effective March 1, 2026, and will remain with Bio-Techne for a period of time to support a smooth transition.

    2/11/26 9:00:00 AM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Emerson to Present at Citi's 2026 Global Industrial Tech and Mobility Conference

    ST. LOUIS, Feb. 11, 2026 /PRNewswire/ -- Emerson (NYSE:EMR) today announced President and Chief Executive Officer, Lal Karsanbhai, and Chief Financial Officer, Mike Baughman, will present at Citi's 2026 Global Industrial Tech and Mobility Conference on Wednesday, February 18th in Miami Beach, Florida. The presentation will begin at 8:50 a.m. Eastern Time, 7:50 a.m. Central Time. The audio will be webcast and archived on Emerson's website at https://ir.emerson.com/. About EmersonEmerson (NYSE:EMR) is a global automation leader delivering solutions for the most demanding technol

    2/11/26 9:00:00 AM ET
    $EMR
    Consumer Electronics/Appliances
    Technology

    $AENT
    $AGIL
    $AIRC
    $AKBA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Scientific Officer Cowan Chad bought $49,252 worth of shares (58,060 units at $0.85), increasing direct ownership by 6% to 1,045,087 units (SEC Form 4)

    4 - Century Therapeutics, Inc. (0001850119) (Issuer)

    12/29/25 4:52:27 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Pfeiffenberger Brent bought $30,352 worth of shares (52,000 units at $0.58), increasing direct ownership by 2% to 3,322,990 units (SEC Form 4)

    4 - Century Therapeutics, Inc. (0001850119) (Issuer)

    12/16/25 6:38:17 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Weisblum Eric bought $2,075 worth of shares (5,000 units at $0.41), increasing direct ownership by 2% to 216,932 units (SEC Form 4)

    4 - Silo Pharma, Inc. (0001514183) (Issuer)

    12/16/25 6:34:59 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    $AENT
    $AGIL
    $AIRC
    $AKBA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Emerson downgraded by Deutsche Bank with a new price target

    Deutsche Bank downgraded Emerson from Buy to Hold and set a new price target of $170.00

    2/5/26 6:53:33 AM ET
    $EMR
    Consumer Electronics/Appliances
    Technology

    Futu Holdings upgraded by Goldman with a new price target

    Goldman upgraded Futu Holdings from Neutral to Buy and set a new price target of $213.39

    2/2/26 6:47:07 AM ET
    $FUTU
    Investment Bankers/Brokers/Service
    Finance

    Church & Dwight upgraded by Analyst with a new price target

    Analyst upgraded Church & Dwight from Underweight to Neutral and set a new price target of $100.00

    2/2/26 6:46:46 AM ET
    $CHD
    Package Goods/Cosmetics
    Consumer Discretionary

    $AENT
    $AGIL
    $AIRC
    $AKBA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 18, 2024 - FDA Roundup: October 18, 2024

    For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c

    10/18/24 4:16:25 PM ET
    $NVCR
    $BAX
    Medical/Dental Instruments
    Health Care

    FDA Approval for VAFSEO issued to AKEBIA THERAPEUTICS INC

    Submission status for AKEBIA THERAPEUTICS INC's drug VAFSEO (ORIG-1) with active ingredient VADADUSTAT has changed to 'Approval' on 03/27/2024. Application Category: NDA, Application Number: 215192, Application Classification: Type 1 - New Molecular Entity

    3/28/24 10:46:38 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AENT
    $AGIL
    $AIRC
    $AKBA
    Leadership Updates

    Live Leadership Updates

    View All

    UGI Corporation Appoints Sidd Manjeshwar as Chief Strategy Officer

    UGI Corporation (NYSE:UGI) today announced that Sidd Manjeshwar has joined as Chief Strategy Officer and serves as part of the company's executive leadership team. In this newly created role, Manjeshwar will be responsible for formulating and driving UGI's enterprise vision and strategy, and leading strategic initiatives including assessing growth opportunities. Robert Flexon, President and CEO of UGI Corporation, said, "Over the past year, we have been focused on operational excellence and business turnaround, to drive greater intrinsic value and solidify our foundation. As we advance this crucial work, Sidd's extensive experience in corporate strategy, M&A, and value creation will help

    2/4/26 5:15:00 PM ET
    $UGI
    Natural Gas Distribution
    Utilities

    Workiva Announces Two New Appointments to Board of Directors

    Company Appoints Former Cisco and Autodesk CFO Scott Herren and Former Workday Co-President, CFO, and EVP Mark Peek Workiva Inc. (NYSE:WK), a leading, AI-powered platform for trust, transparency, and accountability, today announced the appointment of two new independent directors to its Board of Directors. Scott Herren is the former EVP and Chief Financial Officer of Cisco and current Board member and Audit Committee Chair at Rubrik (NYSE:RBRK). Mark Peek is a former EVP, CFO, and Co-President of Workday (NASDAQ:WDAY) and currently sits on the Board of Directors for SentinelOne (NYSE:S) and Trimble (NASDAQ:TRMB). "We are pleased to welcome two highly experienced SaaS leaders to our Boar

    1/28/26 4:05:00 PM ET
    $RBRK
    $S
    $TRMB
    Computer Software: Prepackaged Software
    Technology
    Industrial Machinery/Components
    Industrials

    Tetra Tech Acquires Halvik Corp

    Expanding Its High-End Data Analytics, AI, and Enterprise Tech Services Tetra Tech, Inc. (NASDAQ:TTEK), a leading provider of high-end consulting and engineering services in water, environment, and sustainable infrastructure, announced today that it has acquired Halvik Corp (Halvik), a high-end provider of advisory consulting services focused on advanced data analytics, systems modernization, and cybersecurity for U.S. defense and civilian agencies. "The addition of Halvik expands our high-end analytics and digital solutions across U.S. federal agencies," said Roger Argus, Tetra Tech President and CEO-designate. "Halvik broadens our relationships with the U.S. Army, Navy, Air Force, and

    1/22/26 9:03:00 AM ET
    $TTEK
    Military/Government/Technical
    Consumer Discretionary

    $AENT
    $AGIL
    $AIRC
    $AKBA
    Financials

    Live finance-specific insights

    View All

    Cricut to Announce Fourth Quarter 2025 Financial Results on March 3, 2026

    SOUTH JORDAN, Utah, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Cricut, Inc. ("Cricut") (NASDAQ:CRCT), the creative technology company that has brought a connected platform for making to millions of users worldwide, today announced it will report its financial results for the fourth quarter ended December 31, 2025 after the U.S. markets close on Tuesday, March 3, 2026. Cricut management will host a conference call and webcast to discuss the results that afternoon at 3:00 p.m. Mountain Time (5:00 p.m. Eastern Time). A live webcast of the earnings call will be available on Cricut's investor relations website at https://investor.cricut.com/. A webcast replay will be available after the live event. To

    2/10/26 4:05:00 PM ET
    $CRCT
    Industrial Machinery/Components
    Technology

    Zimmer Biomet Announces Fourth Quarter and Full-Year 2025 Financial Results

    Fourth quarter net sales of $2.244 billion increased 10.9% on a reported basis, 9.2% on a constant currency1 basis and 5.4% on an organic constant currency1 basisFourth quarter diluted earnings per share were $0.70, a decrease of 41.7%; adjusted1 diluted earnings per share were $2.42, an increase of 4.8%Full-year net sales of $8.232 billion increased 7.2% on a reported basis, 6.4% on a constant currency1 basis and 3.9% on an organic constant currency1 basisFull-year diluted earnings per share were $3.55, a decrease of 19.9%; adjusted1 diluted earnings per share were $8.20, an increase of 2.5%Company provides full-year 2026 financial guidanceWARSAW, Ind., Feb. 10, 2026 /PRNewswire/ -- Zimmer

    2/10/26 6:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    UDR, Inc. Announces Fourth Quarter and Full-Year 2025 Results, Establishes 2026 Guidance Ranges and Increases Dividend

    UDR, Inc. (the "Company") (NYSE: UDR), announced today its fourth quarter and full-year 2025 results, and has posted a related Investor Presentation to its website at ir.udr.com. Net Income, Funds from Operations ("FFO"), and FFO as Adjusted ("FFOA") per diluted share for the quarter and full-year ended December 31, 2025, are detailed below.   Quarter Ended December 31 Metric 4Q 2025 Actual 4Q 2025 Guidance 4Q 2024 Actual $ Change vs. Prior Year Period % Change vs. Prior Year Period Net Income per diluted share $0.67 $0.13 to $0.15 $(0.02) $0.69 N/A FFO per diluted share $0.62 $0.63 to

    2/9/26 4:16:00 PM ET
    $UDR
    Real Estate Investment Trusts
    Real Estate

    $AENT
    $AGIL
    $AIRC
    $AKBA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Upwork Inc.

    SC 13G/A - UPWORK, INC (0001627475) (Subject)

    12/9/24 6:02:26 AM ET
    $UPWK
    EDP Services
    Technology

    SEC Form SC 13G filed by Century Therapeutics Inc.

    SC 13G - Century Therapeutics, Inc. (0001850119) (Subject)

    11/27/24 6:51:58 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Tetra Tech Inc.

    SC 13G - TETRA TECH INC (0000831641) (Subject)

    11/21/24 6:04:57 AM ET
    $TTEK
    Military/Government/Technical
    Consumer Discretionary